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ABSTRACT 
 
This study aimed to determine the resistance profile and the nature of multidrug 
resistance in Extended Spectrum Beta Lactamase (ESBL)-producing Escherichia coli 
(E.coli) against several classes of antibiotics. Positive isolates of ESBL-producing E.coli 
were tested for antibiotic sensitivity using the VITEK® 2 compact method which then 
analyzed automatically. The results showed an antibiotic resistance profile against 
ESBL-producing E.coli showed the highest level of antibiotics in beta lactam, 
amoxicillin, ampicillin, cefazolin, cefotaxime, and ceftriaxone at 100%. Subsequent 
results found a relatively high level of resistance in the antibiotics aztreonam (86.36%), 
trimethoprim/sulfamethoxazole (77.27%), gentamicin (72.73%), and ciprofloxacin 
(68.18%). Antibiotics from carbapenem groups such as ertapenem and memenem, and 
antibiotics from the aminoglycosides (amicasin) and tigecycline groups of tetracycline 
still showed a high sensitivity level of 100%. The most common resistance patterns 
found in ESBL-producing E.coli isolates are AM/AMP/KZ/CTX/CRO/ATM/GM/CIP 
as much as 22.73%, and AM/AMP/KZ/CTX/CRO/ATM/GM/CIP/SXT patterns of 
18.2%. The results of multi-class antibiotic resistance showed that 86.36% had 
multidrug resistance. The highest multidrug resistance pattern in ESBL-producing E.coli 
occurred with a BL/AG/Q/SP pattern of 50%. Other patterns of multidrug resistance in 
ESBL-producing E.coli that can be found in this study are, the BL/AG/Q/SP pattern is 
18.20%, the BL/AG/Q/SP pattern is 13.64%, and the BL/AG/Q pattern is 4.55%. The 
high profile of resistance and the nature of multidrug resistance in ESBL-producing 
E.coli has the potential to spread these resistant genes, thus risking the use of antibiotics 
as a public health therapy and animal health, therefore further evaluation and control are 
needed. 
 
Keywords: ESBL-producing Escherichia coli, Multidrug resistance, Vitek® 2 Compact 
Method 
 
 
Introduction 
 
Disease in commercial chicken is one of 
constraints causing the decline in economic value 
(Wiedosari and Wahyuwardani, 2015). Pathogenic 
microorganisms cause infectious diseases, which 
is one of a leading cause of death in animals or 
even human. The high prevalence of infectious 
disease is associated with the high use of 
antibiotic in health care (Noor and Peoleonga, 
2005). A negative economic consequence in 
commercial chicken production can be caused by 
Escherichia coli (E.coli) infection. The existence of 
Extended Spectrum Beta Lactamase (ESBL)-
producing E.coli on commercial chicken is highly 
associated with E.coli, a normal microflora on 
gastrointestinal tract of commercial chicken. 
Feces and animal housing environment can 
facilitate the existence of E.coli, although, chicken 
show no symptoms at all of any diseases caused 
by the bacteria (Wibisono et al., 2018). 
Commercial chicken farm is one of sources 
of antibiotic resistance. The uncontrolled use of 
antibiotic causes the emergence of antibiotic 
resistance. Beta lactam antibiotic is the type of 
antibiotic commonly used in commercial chicken 
production. Resistance to beta lactam antibiotic 
can occur in ESBL-producing E.coli (Santos et al., 
2013; Hammerum et al., 2014). Extended 
Spectrum Beta Lactamase is an enzyme that 
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causes resistance to wider spectrum on third 
generation of cephalosporins and mobobactams; 
thus, the antiobiotic becomes ineffective. ESBL-
producing bacteria can also be resistant to wide 
array of antibiotic class: aminoglycoside, 
tetracycline chloramphenicol, and 
sulfamethoxazole-trimethoprim (Brower et al., 
2017; Sudarwanto et al., 2017). Incidence on 
multidrug resistance to third generation 
cephalosporins and other antibiotic classes are 
often found in ESBL-producing bacteria (Masruroh 
et al., 2016). Multidrug resistance is a resistance 
to three or more different antibiotic classes 
(Handayani et al., 2017). 
Identification of ESBL bacteria is a problem 
in confirming a diagnosis at the laboratory, either 
in therapeutic approach or in the field to prevent 
its spread. Clinical and Laboratory Standards 
Institute (CLSI) states that ESBL examination 
must be performed routinely. According to CLSI 
recommendation, ESBL detection consists of two 
steps. The first is an initial screen test, a filter test 
to reduce the susceptibility to more than one 
cephalosporin indicators (cefotaxime, ceftriaxone, 
ceftazidime, cefpodoxime) and aztreonam. The 
susceptibility reduction from cephalosporins 
shows positive results. A positive result from 
screening test is followed by the second step, 
ESBL confirmation test. The second step aims to 
detect the hydrolytic potency of ESBL against 
antibiotic used in the screening test. The ESBL 
confirmation test deliver a picture of collaboration 
action between ceftazidime or cefotaxime, and 
clavulanate acid (Amelia et al., 2016; CLSI, 2017; 
Biutifasari, 2018).  
Methods of identification, antibiotic 
sensitivity test, and ESBL-producing bacteria 
confirmation test are categorized into phenotype 
and genotype examination methods, with their 
advantages and limitations. Both phenotypic 
bacteria identification and antibiotic sensitivity is 
relatively easier than genotypic examination. 
Phenotypic examination is performed by using 
agar testing method or fully automated automatic 
method as in VITEK® 2 compact automated 
system. The VITEK® 2 compact automated 
system from Biomerieux works on calorimetric 
principle for identification, through biochemical 
and antibiotic sensitivity tests. The accuracy of 
VITEK® 2 compact automated system ranges from 
97.8% (O’Hara, 2005) to 98.02% (Duggal et al., 
2012). This study aimed to determine resistance 
profile and the nature of multidrug resistance in 
ESBL-producing E.coli against several classes of 
antibiotic. Antibiotic resistance is a problem 
occurring across the globe, including Indonesia, 
both in human and animal health. 
 
Materials and Methods 
 
This study used commercial chicken 
cloaca swab sample, collected from commercial 
chicken farms in Blitar Regency. 22 positive 
ESBL-producing E.coli isolate were identified 
using IMBIC test and confirmed as ESBL-
producing E.coli using Double Disc Synergy 
(DDST) test (CLSI, 2017; Effendi et al., 2018). 
Identification of ESBL-producing E.coli isolate was 
performed using VITEK® 2 GN card, while VITEK® 
2 AST cards were used to determine the 
resistance profile. 3 ml of sterile saline solution 
(0.45 – 0.50%; pH 4.5 – 7.0) was put into plastic 
tube aseptically to make a bacterial suspension.  
E. coli isolate was isolated on MacConkey Agar 
(MCA) medium, incubated at 35-37˚C for 20-24 
hours. E. coli isolate was put int saline solution 
using sterile swab to create bacterial suspension. 
Bacterial suspensions were homogenized and 
0.50 – 0.63 McFarland bacterial turbidity were 
made using VITEK® 2 DensiCHEK. These 
bacterial suspensions were inoculated to VITEK® 
2 card no more than after 30 minutes. Bacterial 
suspension tubes and VITEK® 2 cards (GN and 
AST) were placed into special rack or cassette. 
Racks containing bacterial suspensions and cards 
were placed into vacuum chamber station for 30-
60 seconds. Bacterial suspension was then 
transferred into wells. Transfer tubes were cut 
automatically. Cards were transferred to incubator 
room after 15 minutes, for approximately 8 hours 
at 35˚C. Cards were then analyzed automatically. 
Antibiotic sensitivity test on ESBL-producing E.coli 
was carried out using VITEK® 2 compact, that 
consists of 18 antibiotics: amoxicillin, ampicillin, 
ampicillin/sulbactam, piperacillin/tazobactam, 
cefazolin, cefotaxime, ceftazidime, ceftriaxone, 
cefepime, aztreonam, ertapenem, meropenem, 
amikacin, gentamicin, ciprofloxacin, tigecycline, 
nitrofurantoin, dan trimethoprim/sulfamethoxazole. 
The results were automatically analyzed by 
system and interpreted as sensitive, intermediate, 
or resistant (Sugiartha, 2016; Biomerieux, 2017). 
ESBL-producing E.coli multidrug resistance in this 
study used six different antibiotic classes: beta 
lactam, aminoglycoside, quinolone, tetracycline, 
nitrofuran, and sulfonamide-potential. 
 
Results and Discussion 
 
The resistance test results of ESBL-
producing E.coli from commercial chicken cloaca 
swabs against several classes of antibiotic (Figure 
1) shows high level of resistance. The highest 
percentage of resistance was observed in 
amoxicillin, ampicillin, cefazolin, cefotaxime, and 
ceftriaxone, by 100%. This result is according to 
resistance study on ESBL-producing E.coli at 
RPHR of Bogor City that showed 100% level of 
resistance on penicillin and amoxicillin 
(Normaliska et al., 2019). Amoxicillin, ampicillin, 
cefazolin, cefotaxime, and ceftriaxone are 
categorized as beta lactam class antibiotic, 
amoxicillin and ampicillin belong to penicillin, 
cefazolin belongs to first generation 
cephalosporins, cefotaxime and ceftriaxone is 
third generation cephalosporins class. E.coli which 
is often referred as ESBL-producing bacteria has 
ability to produce beta lactamase enzyme, an 
enzyme that able to inhibit beta lactam (Paterson 
and Bonomo, 2005). Beta lactam resistance 
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commonly occurs in gram negative bacteria, 
including E.coli that can be isolated form animal 
products. Poultry is known as ESBL-producing  
E.coli reservoir (Schmid et al., 2013; Hammerum 
et al., 2014). The high resistance level of ESBL-
producing E.coli from commercial chicken cloaca 
swab on beta lactam class antibiotic is caused by 
the presence of ESBL enzyme in E.coli, which is 
not limited on digestive tract, but also in the cage, 
feces, and surrounding environment (Schroeder et 
al., 2004). The enzyme is not only able to 
hydrolyze penicillin, but also third generation 
cephalosporins and monobactam (Paterson and 
Bonomo, 2005; Nuangmek et al., 2018). 
A relatively high level resistance of ESBL-
producing bacteria was observed on aztreonam, 
trime thoprim/sulfamethoxazole, gentamicin, and 
ciprofloxacin, by 86.36%, 77.27%, 72.73%, and 
68.18% consecutively, as the previous study with 
relatively high level of resistance of ciprofloxacin 
(50.0%), gentamicin (60.0%), trimethoprim-
sulfamethoxazole (60%, and ciprofloxacin (40.0%) 
(Cormican et al., 1996; et al.Kürekci et al., 2017; 
Sudarwanto et al., 2017). Other antibiotics such 
as ertapenem and mempenem from carbapenem 
class, amikacin (aminoglycoside class), and 
tigecycline (tetracycline class) still show high level 
of sensitivity (100%), according to mechanism of 
action of ESBL which hydrolyze penicilin class 
antibiotics, first, second, and third generations of 
cephalosporin, and monobactam antibiotic class, 
but inactive on carbapenem class (imipenem, 
meropenem, ertapenem) (Lim et al., 2013; 
Biutifasari, 2018). Nitrofurantoin has lower 
resistance level than trimethoprim-
sulphamethoxazole and fluoroquinolone (Rank et 
al., 2018). 
The susceptibility result shows a nearly 
similar pattern for all isolates (Table 1). The most 
resistance pattern seen on ESBL-producing E.coli 
was AM/AMP/KZ/CTX/CRO/ATM/GM/CIP pattern 
(22.73% or 5/22), and 
AM/AMP/KZ/CTX/CRO/ATM/GM/CIP/SXT (18.2% 
or 4/22). The result of t multiclass antibiotic 
resistance shows 86.36% (19/22) had multidrug 
resistance (Table 2). Multidrug resistance is 
certain bacterial resistance to three or more 
different antibacterial class (Kurniawati et al., 
2015). Multidrug resistance is a problem that hard 
to resolve in disease treatment. This condition is 
caused by the practice of the antibiotic use as 
disease preventive measures in commercial 
chicken production. Antibiotic has been used to 
control the level of morbidity, mortality, and 
infection of E.coli. While antibiotics are mostly 
used as therapeutic, several antibiotic classes are 
used for sub therapeutic purpose to prevent the 
emergence of disease in animal production 
(Niasono et al., 2019). The use of antibiotic at sub 
therapeutic level can lead to the emergence of 
multidrug resistance (Wang et al., 2015). 
The highest level of multidrug resistance 
patter of ESBL-producing E.coli was observed on 
BL/AG/Q/SP pattern (50% or 11/22). Other 
multidrug resistance patterns found in this study 
were BL/AG/Q/SP (18.20% or 4/22), BL/AG/Q/SP 
(13.64% or 3/22), and BL/AG/Q (4.55% or 1/22). 
This study demonstrates that the high incidence of 
multidrug resistance can indicate the high risk of 
transmission on other chicken at the farm, to 
cause a transmission of antibiotic resistance on 
multi class antibiotics. The condition can result in 
the high potential failure of antibiotic treatment
 
 
Figure 1. Resistance profiles of ESBL-producing E.coli using VITEK® 2 method 
(Amoxicillin = AM; Ampicillin = AMP; Ampicillin/sulbactam = SAM; Piperacillin/Tazobactam = TZP; Cefazolin = KZ; Cefotaxime = CTX; 
Ceftazidime = CAZ; Ceftriaxone = CRO; Cefepime = FEP; Aztreonam = ATM; Ertapenem = ERT; meropenem = MEM; amikacin = AK; 
gentamicin = GM; ciprofloxacin = CIP; tigecycline = TC; nitrofurantoin = NFT; trimethoprim/sulfamethoxazole = SXT; R = Resistance; I = 
Intermediate; S = Susceptible) 
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Table 1. Isolates belonging to individual antibiotic resistance profiles 
 
 
Code  
  Antibiotic   
 
Anti-microbial 
Resistance Profiles 
A 
M 
A 
M 
P 
S 
A 
M 
T 
Z 
P 
K 
Z 
C 
T 
X 
C 
A 
Z 
C 
R 
O 
F 
E 
P 
A 
T 
M 
E 
R 
T 
M 
E 
M
  
A 
K 
G 
M 
C 
I 
P 
T 
C 
N 
F 
T 
S 
X 
T 
Ec1 R R S S R R S R S R S S S R R S S S AM/AMP/KZ/CTX/CRO
/ATM/GM/CIP 
Ec2 R R S S R R S R S R S S S R R S S R AM/AMP/KZ/CTX/CRO
/ATM/GM/CIP/SXT 
Ec3 R R S S R R S R S R S S S R R S S R AM/AMP/KZ/CTX/CRO
/ATM/GM/CIP/SXT 
Ec4 R R I S R R S R S R S S S R R S I S AM/AMP/KZ/CTX/CRO
/ATM/GM/CIP 
Ec5 R R S S R R S R S R S S S R R S S R AM/AMP/KZ/CTX/CRO
/ATM/GM/CIP/SXT 
Ec6 R R I S R R S R S S S S S R R S S S AM/AMP/KZ/CTX/CRO
/ATM/GM/CIP 
Ec7 R R R S R R R R S R S S S S I S S R AM/AMP/SAM/KZ/CTX
/CAZ/CRO/ATM/SXT 
Ec8 R R S S R R S R S R S S S R S S S R AM/AMP/KZ/CTX/CRO
/ATM/GM/SXT 
Ec9 R R I S R R S R S R S S S R S S S R AM/AMP/KZ/CTX/CRO
/ATM/GM/SXT 
Ec10 R R S S R R S R S S S S S R S S I R AM/AMP/KZ/CTX/CRO
/GM/SXT 
Ec11 R R I S R R S R S S S S S R R S S R AM/AMP/KZ/CTX/CRO
/GM/CIP/SXT 
Ec12 R R I S R R S R S R S S S R R S I S AM/AMP/KZ/CTX/CRO
/ATM/GM/CIP 
Ec13 R R S S R R S R S R S S S R R S S R AM/AMP/KZ/CTX/CRO
/ATM/GM/CIP/SXT 
Ec14 R R S S R R S R S R S S S R R S S S AM/AMP/KZ/CTX/CRO
/ATM/GM/CIP 
Ec15 R R S S R R S R S R S S S S I S S R AM/AMP/KZ/CTX/CRO
/ATM/SXT 
Ec16 R R I S R R R R R R S S S R R S S R AM/AMP/KZ/CTX/CAZ/
CRO/FEP/ATM/GM/CI
P/SXT 
Ec17 R R R I R R R R R R S S S S R S I R AM/AMP/SAM/KZ/CTX
/CAZ/CRO/FEP/ATM/
CIP/SXT 
Ec18 R R R S R R R R R R S S S R R S S R AM/AMP/SAM/KZ/CTX
/CAZ/CRO/FEP/ATM/
GM/CIP/SXT 
Ec19 R R R S R R R R R R S S S S R S I R AM/AMP/SAM/KZ/CTX
/CAZ/CRO/FEP/ATM/
CIP/SXT 
Ec20 R R R I R R R R R R S S S I S S I R AM/AMP/SAM/KZ/CTX
/CAZ/CRO/FEP/ATM/S
XT 
Ec21 R R R S R R S R S R S S S R S S S R AM/AMP/SAM/KZ/CTX
/CRO/ATM/GM/SXT 
Ec22 R R I S R R R R R R S S S S R S S R AM/AMP/KZ/CTX/CAZ/
CRO/FEP/ATM/CIP/S
XT 
 Total                                       
R 22 22 6 0 22 22 7 22 6 19 0 0 0 1
6 
1
5 
0 0 1
7 
 
I 0 0 7 2 0 0 0 0 0 0 0 0 0 1 2 0 6 0  
S 0 0 9 20 0 0 15 0 16 3 2
2 
2
2 
2
2 
5 5 2
2 
1
6 
5  
(Amoxicillin = AM; Ampicillin = AMP; Ampicillin/sulbactam = SAM; Piperacillin/Tazobactam = TZP; Cefazolin = KZ; Cefotaxime = CTX; Ceftazidime = CAZ; 
Ceftriaxone = CRO; Cefepime = FEP; Aztreonam = ATM; Ertapenem = ERT; meropenem = MEM; amikacin = AK; gentamicin = GM; ciprofloxacin = CIP; 
tigecycline = TC; nitrofurantoin = NFT; trimethoprim/sulfamethoxazole = SXT; R = Resistance; I = Intermediate; S = Susceptible) 
 
Table 2. Multidrug resistance pattern of ESBL-producing E.coli isolate 
Sample 
code 
Beta 
lactam 
Aminoglycoside Quinolones Tetracycline Nitrofuran Sulfonamide 
potential 
MDR Multidrug 
Resistance Pattern 
Ec1 R R R S S S MDR BL/AG/Q 
Ec2 R R R S S R MDR BL/AG/Q/SP 
Ec3 R R R S S R MDR BL/AG/Q/SP 
Ec4 R R R S I S MDR BL/AG/Q 
Ec5 R R R S S R MDR BL/AG/QSP 
Ec6 R R R S S S MDR BL/AG/Q/NF/SP 
Ec7 R S I S S R NEGATIF BL/SP 
Ec8 R R S S S R MDR BL/AG/SP 
Ec9 R R S S S R MDR BL/AG/SP 
Ec10 R R S S I R MDR BL/AG/SP 
Ec11 R R R S S R MDR BL/AG/Q/SP 
Ec12 R R R S I S MDR BL/AG/Q 
Ec13 R R R S S R MDR BL/AG/Q/SP 
Ec14 R R R S S S MDR BL/AG/Q 
Ec15 R S I S S R NEGATIF BL/SP 
Ec16 R R R S S R MDR BL/AG/Q/SP 
Ec17 R S R S I R MDR BL/AG/Q/SP 
Ec18 R R R S S R MDR BL/AG/Q/SP 
Ec19 R S R S I R MDR BL/AG/Q/SP 
Ec20 R I S S I R NEGATIF BL/SP 
Ec21 R R S S S R MDR BL/AG/SP 
Ec22 R S R S S R MDR BL/AG/Q/SP 
(Beta laktam = BL; Aminoglycoside = AG; Quinolones = Q; Tetracycline = TC; Nitrofuran = NF; Sulfonamide potensial = SP; R = Resistance; I = Intermediate; 
S = Susceptible). 
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during the existence of infectious disease at the 
farm. The different resistance pattern arises due 
to the varied antibiotic combinations used by 
farmers, as stated by Bywater et al. (2014) in 
which various type of antibiotics, geographic 
conditions, and production system are factors 
causing the different resistance pattern. 
 
Conclusion 
 
The highest antibiotic resistance of ESBL-
producing E.coli was observed on amoxicillin, 
ampicillin, cefazolin, cefotaxime, and ceftriaxone 
(100%). Ertapenem and mempenem from 
carbapenem antibiotic class, and amikacin 
(aminoglycoside class), and tigecycline 
(tetracycline class) still display high sensitivity 
(100%). The most resistance pattern found in this 
study was AM/AMP/KZ/CTX/CRO/ATM/GM/CIP 
(22.73%), and 
AM/AMP/KZ/CTX/CRO/ATM/GM/CIP/SXT 
(18.2%). The result of multi class antibiotic 
resistance exhibits 86.36% are multidrug resistant, 
with the highest multidrug resistance occurred in 
BL/AG/Q/SP (50%). 
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